- Home
- PHH vs PLX Comparison
PHH vs PLX Comparison
Compare PHH & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHH
- PLX
- Stock Information
- Founded
- PHH 2016
- PLX 1993
- Country
- PHH China
- PLX Israel
- Employees
- PHH N/A
- PLX N/A
- Industry
- PHH Package Goods/Cosmetics
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHH Consumer Discretionary
- PLX Health Care
- Exchange
- PHH Nasdaq
- PLX Nasdaq
- Market Cap
- PHH 160.1M
- PLX 160.2M
- IPO Year
- PHH 2024
- PLX 1998
- Fundamental
- Price
- PHH $5.44
- PLX $2.39
- Analyst Decision
- PHH
- PLX Strong Buy
- Analyst Count
- PHH 0
- PLX 1
- Target Price
- PHH N/A
- PLX $15.00
- AVG Volume (30 Days)
- PHH 41.8K
- PLX 646.5K
- Earning Date
- PHH 01-01-0001
- PLX 03-13-2025
- Dividend Yield
- PHH N/A
- PLX N/A
- EPS Growth
- PHH N/A
- PLX N/A
- EPS
- PHH 0.02
- PLX N/A
- Revenue
- PHH $1,940,443.00
- PLX $45,667,000.00
- Revenue This Year
- PHH N/A
- PLX N/A
- Revenue Next Year
- PHH N/A
- PLX $63.84
- P/E Ratio
- PHH $357.67
- PLX N/A
- Revenue Growth
- PHH 108.42
- PLX N/A
- 52 Week Low
- PHH $3.70
- PLX $0.82
- 52 Week High
- PHH $6.90
- PLX $2.76
- Technical
- Relative Strength Index (RSI)
- PHH N/A
- PLX 48.43
- Support Level
- PHH N/A
- PLX $2.43
- Resistance Level
- PHH N/A
- PLX $2.73
- Average True Range (ATR)
- PHH 0.00
- PLX 0.13
- MACD
- PHH 0.00
- PLX -0.04
- Stochastic Oscillator
- PHH 0.00
- PLX 13.95
About PHH Park Ha Biological Technology Co. Ltd. Ordinary Shares
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries specialize in providing skincare and cosmetic products under its brand name Park Ha in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complimentary after-sales beauty services in its physical stores.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.